accountinhibitor class of diabetes drugs but hit the market well before Onglyza. Meanwhile, in February Bristol-Myers and partner Eli Lilly and Co. stopped enrolling patients in one of two late-stage studies of the potential cancer treatment necitumumab, for...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Earnings Preview: Bristol-Myers reports 1Q results
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account